Received Oct 14, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 4 | — | — |
| VARZOS | ZOSTER (SHINGRIX) | GLAXOSMITHKLINE BIOLOGICALS | 3 | — | — |
Multiple doses; Multiple doses; This non-serious case was reported by a pharmacist via call center representative and described the occurrence of extra dose administered in a 76-year-old female patient who received Herpes zoster (Shingrix) for prophylaxis. Co-suspect products included Herpes zoster (Shingrix) for prophylaxis. Previously administered products included Shingrix (received 1st dose on 06-SEP-2019) and Shingrix (received 2nd dose on 21-DEC-2019). On 01-JUN-2022, the patient received the 3rd dose of Shingrix. On 02-SEP-2022, the patient received the 4th dose of Shingrix. On 01-JUN-2022, an unknown time after receiving Shingrix and not applicable after receiving Shingrix, the patient experienced extra dose administered (Verbatim: Multiple doses). On 02-SEP-2022, the patient experienced extra dose administered (Verbatim: Multiple doses). The outcome of the extra dose administered and extra dose administered were not applicable. Additional Information: GSK receipt Date: 06-OCT-2025 The pharmacist reported that looked at the patient profile recently and noticed she got 2 rounds of the Shingrix vaccine one in 2019 2 shots again in 2022, wondering what harm the patients would have in getting 4 shots in the system. The reporter did not know if there was some lag and guess between the patient did not know she received it and the system did not show she already received it so we administered to her again. The reporter was ask any side effects or what do we tell to the patient. The batch number was not provided upon follow up with the reporter.